DEC 27 2005

CERTIFICATE OF MAILING

eby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing

ELI LILLY AND COMPANY

ecember 21, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. Patent No.

6,977,077

Issued:

December 20, 2005

First Applicant

Hock; Janet M.

Serial No.

09/647,278

Application Date

September 26, 2000

Entitled

Method of increasing bone toughness and stiffness

and reducing fractures

Docket No.

X-11965

REQUEST FOR CERTIFICATE OF CORRECTION **UNDER 37 C.F.R. 1.322**

ATTN: CERTIFICATE OF CORRECTION BRANCH Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The Patentee of the above-identified patent respectfully requests issuance of a Certificate of Correction, pursuant to 37 C.F.R. 1.323, to correct an error in the printing of Claim 1 of the patent. The Patentee respectfully asserts that the error in printing Claim 1 occurred as a result of action by the PTO. Claim 1 should be corrected to comport with Claim 1 as stipulated in the Supplemental Examiner's Amendment (Paper No. 05232005), dated June 3, 2005, attached hereto for reference. Also attached herewith are two copies of Form PTO 1050 on which the error is specified.

If the error is not deemed to be the result of PTO error, please charge the amount of \$100 (fee under 1.20(a)), and any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 to cover

the cost of this Certificate of Correction. An original and two copies of this Request are enclosed.

Respectfully submitted,

Thomas D. Webster, PhD, JD

Attorney for Patentee Registration No. 39,872

Phone: 317-276-3334

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

December 21, 2005

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.	:	6,977,077	·			
DATED	:	December 20, 2005				
INVENTOR(S)	: .	Hock, Janet M. et al.				
It is certified th	at an error app	pears in the above-identified	patent and that said	Letters Paten	t is hereby cor	ected as shown
Claim 1 should read	as follows:	±.,				•
hormone (1-34) in a	daily dose of 2	steoporosis in a human subje 20 µg, without concurrent ad g the risk of vertebral and no	ministration of an ar	ntiresorptive a	aid subject hum agent other than	nan parathyroid 1 vitamin D or
			•		•	
,						
	•				·	
		·			•	
٠.						
				• .	•	

PATENT NO.

MAILING ADDRESS OF SENDER:

JAN 05 2006

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

FORM PTO 1050

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.	:	6,977,077	•			
DATED	:	December 20, 2005				
INVENTOR(S)	:	Hock, Janet M. et al.	• .			
It is certified that	an error a	appears in the above-identific	ed patent and that said I	Letters Patent is ho	ereby corrected as shown	
Claim 1 should read as	follows:	e i				
ormone (1-34) in a da	aily dose o	osteoporosis in a human sub of 20 μg, without concurrent cing the risk of vertebral and	administration of an an	tiresorptive agent	bject human parathyroid other than vitamin D or	
				•		
					•	
						*
	•					
			•			
		, ·		·		
MAILING ADDRESS O	E SENDE	R:	PATENT NOU.	S. 6,977,077		

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

FORM PTO 1050





UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR I PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.	
091647,278	09/26/2000	Janet M. Hock		X-11965	
			EXAMINER		
		• .		Ruixiang Li	
		•	ART UNIT	PAPER	
			1646	05232005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

During a telephone interview with Applicants' representative Thomas D. Webster on May 23, 2005, the limitation of claim 35, "wherein said vitamin D is not a hydroxylated vitamin D or hydroxylated vitamin D metabolite", was discussed. Applicants agreed to amend the claim to delete this limitation and to pay the issue fee within three months from the mailing date of the original notice of allownce, i.e. 05/11/2005 (see attached supplemental Examiner's amendment and telephone interview summary).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (571) 272-0829. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect uspto gov. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruxans

Ruixiang Li Examiner May 23, 2005

PTO-90C (Rev 04-03)

JAN 0 5 2006

Art Unit: 1646

SUPPLEMENTAL EXAMINER'S AMENDMENT

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37

CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no

later than the payment of the issue fee. Authorization for this examiner's amendment

was given in a telephone interview with Thomas D. Webster on May 23, 2005.

Amendment to claim 35:

Claim 36 A method for the treatment of osteoporosis in a human subject, comprising

administering to said subject human parathyroid hormone (1-34) in a daily dose of 20

μg, without concurrent administration of an antiresorptive agent other than vitamin D or

calcium, said treatment for reducing the risk of vertebral and non-vertebral bone

fracture.

Issue Fee

During the telephone interview with Thomas D. Webster on May 23, 2005, Applicants

also agreed to pay the issue fee and publication fee within three months from the

mailing date of the original notice of allowance, i.e., 05/11/2005.

BEST AVAILABLE COPY

1AN 0 5 2006

Application/Control Number: 09/647,278

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Anthony Caputa, can be reached on (571) 272-0961. The fax number for the

organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, please contact the Electronic

Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruisiang L

Ruixiang Li, Ph.D.

Examiner

May 23, 2005

BEST AVAILABLE COPY

JAN 0 5 2006

Page 3

	Application No.	Applicant(s)
Examiner-Initiated Interview Summary	09/647,278	HOCK ET AL.
Exammer-initiated interview Summary	Examiner	Art Unit
	Ruixiang Li	1646
All Participants:	Status of Application	n:
(1) <u>Ruixiang Li</u> .	(3)	
(2) Thomas D. Webster.	(4)	
Date of Interview: 23 May 2005	Time:	
Type of Interview: ☑ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applic	ant's representative)	
Exhibit Shown or Demonstrated: Yes No If Yes, provide a brief description:		
Part I.		
Rejection(s) discussed:		
	,	
Claims discussed: 35		
Prior art documents discussed:	•	
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	ERAL NATURE OF WHAT	WAS DISCUSSED:
Part III.		•
 ☑ It is not necessary for applicant to provide a separate directly resulted in the allowance of the application. To of the interview in the Notice of Allowability. ☐ It is not necessary for applicant to provide a separate did not result in resolution of all issues. A brief summation 	ne examiner will provide a	written summary of the substance of the interview
^		
Puiscon C. La-		

U.S. Patent and Trademark Office PTOL-413B (04-03)

(Examiner/SPE Signature)

Examiner Initiated Interview Summary

Paper No. 05232005



(Applicant/Applicant's Representative Signature - if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The limitation of claim 35, "wherein said vitamin D is not a hydroxylated vitamin D or hydroxylated vitamin D metabolite", was discussed. Applicants disagreed that this limitation introduces new matter. Nonetheless, Applicants agreed to amend the claim to delete this limitation. Applicant also agreed to pay the issue fee and publication fee within three months from the mailing date of the notice of allownce, i.e. 05/11/2005.

BEST AVAILABLE COPY